Tracer library / [177Lu]Lu-Ibu-DAB-PSMA
[177Lu]Lu-Ibu-DAB-PSMA
Also written as [Lu-177]Lu-Ibu-DAB-PSMA
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 2
What it is
- Compound class
- PSMA-targeting albumin-binding radioligand (urea-based PSMA inhibitor conjugated with ibuprofen and DAB linker)
- Target / mechanism
- PSMA (prostate-specific membrane antigen) targeting radioligand with albumin-binding moiety PMID 34402925
- Clinical application
- Radioligand therapy of prostate cancer (preclinical, potential for clinical translation) PMID 35635566
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | ≥ 98% | Ibu-DAB-PSMA | 35635566 2022 Eur J Nucl Med Mol Imaging The radiolabeling of the PSMA ligands with lutetium-177 (no-carrier-added; in 0.04 M HCl; ITM Medical Isotopes GmbH, Germany) was performed under standard labeling conditions at pH 4.5 as previously reported |
| Manual synthesis | — | none | — | ≥ 95% | Ibu-DAB-PSMA | 34402925 2022 Eur J Nucl Med Mol Imaging The radiolabeling of Ibu-DAB-PSMA and PSMA-617 was performed under standard labeling conditions at pH 4.5 using lutetium-177 |
Need this precursor?We can point you to suppliers for [177Lu]Lu-Ibu-DAB-PSMA, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35635566: 'Ibu-DAB-PSMA modified with ibuprofen (Ibu) (green) as an albumin-binding entity conjugated via a linker entity composed of a diaminobutyric acid (DAB) and a lysine residue'. Stage set/updated at stage 23 from PMID 34402925: 'This preclinical study underline the relevance of the tumor model and applied ligand amount for the characterization of PSMA radioligands.'.